ALK-Abelló


	Home Contact Site index


Search

Products for diagnosis, prevention and treatment of allergies

Welcome to
the ALK-Abelló
corporate website

Other ALK-Abelló sites

Visit the investor site of ALK-Abelló

Positive third year results with GRAZAX®

ALK-Abelló announces highly significant and positive third year results from clinical study with GRAZAX® which support expectations of a long-term disease-modifying effect of the therapy....>> more

2007 Annual Report
English
Danish

Congress activities 2008
Calendar & scientific contributions

Specific Allergy Symposium (SOSA)
Copenhagen, 24-26 April 08

GRAZAX® Demonstrates Significant Reductions on Asthma Symptoms in Children
In addition to effects on allergic rhinitis (hayfever), GRAZAX® demonstrates significant reductions in asthma symptoms in children aged 5 to 16 years-old

Three-month interim report (Q1) 2008 (unaudited)
Financial performance in the three months ended March 31, 2008

Report on the Annual General Meeting of ALK-Abelló A/S held on April 24, 2008
The AGM of ALK-Abelló A/S held on April 24, 2008 transacted the following business


	ALK-Abelló A/S \| 6-8 Bøge Allé \| DK-2970 Hørsholm \| CVR no. 63 71 79 16 \| Tel. +45 4574 7576


Legal disclaimer Print page